Aortic and mitral valve replacement using the Carpentier-Edwards bioprosthesis resulted in 5-year actuarial survival rates of 87.9% and 91.1%, respectively, with low rates of thromboembolism.
Cohort (n=813)
The Carpentier-Edwards bioprosthesis demonstrated favorable 5-year survival and low thromboembolic rates for both aortic and mitral valve replacements.
Absolute Event Rate: 87.9% vs 91.1%
813 patients underwent aortic (AVR) or mitral valve replacement using the Carpentier-Edwards bioprosthesis from 1976 to 1983. Operative mortality was 5.49% for AVR and 4.59% for MVR. Late mortality and complications were classified using criteria described by the Stanford Group. Actuarial survival at 5 years was 87.9% +/- 2.7% for AVR and 91.1% +/- 1.4% in MVR. Thromboembolism occurred at low rates of 0.48% pt yr for AVR and 0.90% pt yr for MVR. 98.2% +/- 0.90% of AVR and 96.9% +/- 1.3% of MVR pts were free from thromboembolism at 5 years. The low incidence of thromboembolism during the early postoperative period played a role in the low rates observed in the complete study. There was no valve thrombosis. Anticoagulation with warfarin was used in 35% AVR and 75% MVR with rates of bleeding complications of 1.20% pt yr and 1.10% pt yr. Overall valve failure rate was 2.04% pt yr at 5 years for AVR and 1.55% pt yr for MVR. Rates of reoperation for tissue failure remained low (0.24% pt yr for AVR and 0.32% pt yr for MVR). The advantage of a low rate of thromboembolism was not outweighed by the specific problems of bioprosthesis at 5 years.
Soots et al. (Tue,) conducted a cohort in Aortic or mitral valve disease requiring replacement (n=813). Aortic valve replacement with Carpentier-Edwards bioprosthesis vs. Mitral valve replacement with Carpentier-Edwards bioprosthesis was evaluated on Actuarial survival at 5 years. Aortic and mitral valve replacement using the Carpentier-Edwards bioprosthesis resulted in 5-year actuarial survival rates of 87.9% and 91.1%, respectively, with low rates of thromboembolism.